A Phase 3 interventional study of MenACYW conjugate vaccine and MenACYW-135 conjugate vaccine in Healthy Volunteers (Meningococcal Infection), sponsored by Sanofi Pasteur, a Sanofi Company. Completed at 70 sites in 2 countries. Open to participants aged 42 Days to 89 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-15.
Sponsored by Sanofi Pasteur, a Sanofi Company (part of Sanofi) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 57 studies in Meningococcal Infections by Sanofi — 2 open to participants now, 2 under way, 1 of them phase 3. Meningococcal Infections · Sanofi.
Among the 57 studies in Meningococcal Infections by Sanofi, this one is the 4th largest by enrollment of the 51 interventional ones that give a count, is one of 7 that started in 2018, is one of 25 in phase 3, and was the 46th registered.
243 studies on the registry are indexed under Meningococcal Infections; 8 are open to participants now.
Browse Meningococcal Infections studies →2 of the 57 studies in Meningococcal Infections by Sanofi are open now, in 2 countries. Recruiting first, the newest first:
Sanofi · Sites in China
Ages 2 mo–23 mo · Healthy volunteers
Sanofi Pasteur, a Sanofi Company · Sites in United States
Healthy volunteers
By country, each count listing its studies:
Of the 7 Meningococcal Infections studies recruiting now, 3 set no upper age limit and 4 stop at 75 or younger; 4 take children under 18; 6 take healthy volunteers.
This study: 42 Days to 89 Days · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
57 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 17 · Phase 3 25 · Phase 4 8
First in 2002; this study’s year is marked. 7 started in 2018.
This study's enrollment of 2,627 is above the median of 456 across 214 interventional studies indexed under Meningococcal Infections.
Median enrollment 378 across the 51 interventional studies, 440 across the 6 observational. Of the 55 that completed or were terminated, 51 (93%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Sanofi Pasteur, a Sanofi Company, one of the names counted as Sanofi. Under that name alone:
Sanofi Pasteur, a Sanofi Company is the lead sponsor of 374 studies on the registry; 4 are open to participants now.
Of its 94 completed or terminated interventional studies of FDA-regulated products, 73 (78%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 57 studies in Meningococcal Infections by Sanofi, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to compare the immunogenicity and describe the safety of MenACYW conjugate vaccine and MENVEO® when both are administered concomitantly with routine pediatric vaccines to healthy infants and toddlers in the US.
The duration of each subject's participation in the trial was approximately 16 to 19 months (Subgroup 1a) and 19 to 22 months (Subgroup 1b and Group 2), which included a safety follow up contact at 6 months after the last vaccinations.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MenACYW conjugate vaccine and routine vaccines at 2, 4, 6, and 12 to 15 months of age
Biological: MenACYW conjugate vaccine · Biological: DTaP-IPV//Hib vaccine · Biological: Pneumococcal 13-valent conjugate vaccine · Biological: Pentavalent rotavirus vaccine · Biological: Hepatitis B vaccine · Biological: Measles, mumps, rubella (MMR) vaccine · Biological: Varicella vaccine
MenACYW conjugate vaccine at 2, 4, 6, and 15 to 18 months of age and routine vaccines at 2, 4, 6, 12 to 15 months of age, and 15 to 18 months of age
Biological: MenACYW conjugate vaccine · Biological: DTaP-IPV//Hib vaccine · Biological: Pneumococcal 13-valent conjugate vaccine · Biological: Pentavalent rotavirus vaccine · Biological: Hepatitis B vaccine · Biological: Measles, mumps, rubella (MMR) vaccine · Biological: Varicella vaccine · Biological: Hepatitis A vaccine
MENVEO® at 2, 4, 6, and 12 months of age and routine vaccines at 2, 4, 6, 12, and 15 to 18 months of age
Biological: MenACYW-135 conjugate vaccine · Biological: DTaP-IPV//Hib vaccine · Biological: Pneumococcal 13-valent conjugate vaccine · Biological: Pentavalent rotavirus vaccine · Biological: Hepatitis B vaccine · Biological: Measles, mumps, rubella (MMR) vaccine · Biological: Varicella vaccine
MENVEO® at 2, 4, 6, and 12 months of age and routine vaccines at 2, 4, 6, 12, and 15 to 18 months of age
Biological: MenACYW-135 conjugate vaccine · Biological: DTaP-IPV//Hib vaccine · Biological: Pneumococcal 13-valent conjugate vaccine · Biological: Pentavalent rotavirus vaccine · Biological: Hepatitis B vaccine · Biological: Measles, mumps, rubella (MMR) vaccine · Biological: Varicella vaccine · Biological: Hepatitis A vaccine
Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid conjugate vaccine 0.5 mL, intramuscular
Meningococcal (Groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine, 0.5 mL, intramuscular
Also known as: MENVEO®
Drug page: Pentacel
DTaP-IPV//Hib vaccine at 2, 4, 6 and 12 to 15 (Group 1a)/15-18 (Group 1b and Group 2) months of age Intramuscular
Also known as: Pentacel®
Pneumococcal vaccine at 2, 4, 6, and 12 months of age, Intramuscular
Also known as: PREVNAR 13®
Rotavirus vaccine at 2, 4, and 6 months of age, oral solution
Also known as: RotaTeq®
Hepatitis B vaccine at 2 and 6 months of age, Intramuscular
Also known as: ENGERIX-B®
MMR vaccine at 12 months of age, Subcutaneous
Also known as: M-M-R® II
Varicella vaccine at 12 months of age
Also known as: VARIVAX®
Hepatitis A vaccine at 15 to 18 months of age
Also known as: HAVRIX®
Groups 1a and 2a: Percentage of Participants With Vaccine Seroresponse Measured by Serum Bactericidal Assay Using Human Complement (hSBA) at Day 30 Post 12-Month Vaccination
Functional meningococcal antibody activity against serogroups A, C, Y, and W were measured in a serum bactericidal assay utilizing the hSBA. Vaccine seroresponse was defined as a post 4th dose (Day 30 after 12-month) hSBA titer \>=1:16 for participants with pre 1st dose (Day 0 before 2-month) hSBA titer less than (\<) 1:8, or at least a 4-fold increase in hSBA titer from pre-vaccination to post-vaccination for participants with pre-vaccination hSBA titer \>=1:8. Percentages are rounded off to the tenth decimal place.
Time frame: Day 30 post 12-month vaccination (Month 13)
Groups 1 and 2: Percentage of Participants Who Achieved Antibody Titers >=1:8 by hSBA at Day 30 Post 6-Month Vaccination
Functional meningococcal antibody activity against serogroups A, C, Y, and W were measured in a serum bactericidal assay utilizing the hSBA. Percentages are rounded off to the tenth decimal place.
Time frame: Day 30 post 6-month vaccination (Month 7)
Groups 1 and 2: Percentage of Participants Who Achieved Anti-Hepatitis B Antibody Concentrations >=10 Milli-International Units Per Milliliter (mIU/mL) at Day 30 Post 6-Month Vaccination
Anti-Hepatitis B surface antibodies (HBsAg) were measured by the commercially available VITROS ECi/ECiQ immunodiagnostic system using chemiluminescence detection technology. The percentage of participants with an anti-HBsAg antibody titer \>=10 mIU/mL was assessed. Percentages are rounded off to the tenth decimal place.
Time frame: Day 30 post 6-month vaccination (Month 7)
Groups 1 and 2: Percentage of Participants Who Achieved Anti-Polyribosyl-Ribitol (PRP) Antibody Concentrations >=0.15 and >=1.0 Microgram (mcg)/mL at Day 30 Post 6-Month Vaccination
Anti-PRP concentrations were measured using a farr-type radioimmunoassay (RIA). The percentage of participants with an PRP antibody titer \>=0.15 mcg/mL and \>=1.0 mcg/mL were assessed. Percentages are rounded off to the tenth decimal place.
Time frame: Day 30 post 6-month vaccination (Month 7)
Groups 1 and 2: Percentage of Participants Who Achieved Anti-Poliovirus Antibody Titers >=1:8 at Day 30 Post 6-Month Vaccination
Anti-poliovirus types 1, 2, and 3 were measured by neutralization assay. The percentage of participants with anti-polio antibody titers \>=1:8 were assessed.
Time frame: Day 30 post 6-month vaccination (Month 7)
Groups 1 and 2: Percentage of Participants Who Achieved Anti-Rotavirus Immunoglobulin A (IgA) Antibody Concentrations >=3-Fold Rise at Day 30 Post 6-Month Vaccination
Anti-rotavirus IgA antibodies in human serum were measured by enzyme-linked immunosorbent assay (ELISA). The percentage of participants who achieved anti-rotavirus IgA Ab concentrations \>=3-fold rise were assessed. Percentages are rounded off to the tenth decimal place.
Time frame: Day 30 post 6-month vaccination (Month 7)
Groups 1 and 2: Geometric Mean Concentrations (GMCs) of Anti-Rotavirus IgA Antibodies at Day 30 Post 6-Month Vaccination
GMCs of anti-rotavirus serum IgA antibodies were assessed using ELISA.
Time frame: Day 30 post 6-month vaccination (Month 7)
Groups 1 and 2: GMCs of Anti-Pertussis Antibodies at Day 30 Post 6-Month Vaccination
GMCs of anti-pertussis antibodies (pertussis toxoid \[PT\], filamentous hemagglutinin adhesin \[FHA\], pertactin \[PRN\] and fimbriae types 2 and 3 \[FIM\]) were measured by electrochemiluminescent (ECL) assay.
Time frame: Day 30 post 6-month vaccination (Month 7)
Groups 1 and 2: GMCs of Anti-Pneumococcal Antibodies at Day 30 Post 6-Month Vaccination
GMCs of anti-pneumococcal antibodies was assessed by pneumococcal capsular polysaccharide (PnPS) IgG ECL assay which is used to quantitate the amount of anti-streptococcus pneumoniae PS (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) antibodies in human serum.
Time frame: Day 30 post 6-month vaccination (Month 7)
Groups 1a and 2a: Percentage of Participants Who Achieved Vaccine Response for Measles, Mumps and Rubella (MMR) Antibodies at Day 30 Post 12-Month Vaccination
Vaccine response against anti-measles and anti-rubella antibodies were measured by bulk IgG enzyme immunoassay and anti-mumps antibodies were assessed by ELISA. Percentage of participants with anti-measles, anti-mumps, anti-rubella antibody concentration that met the respective mentioned criterion are reported: measles: \>=255 mIU/mL; mumps: \>=10 antibody units per milliliter and rubella: \>=10 IU/mL. Percentages are rounded off to the tenth decimal place.
Time frame: Day 30 post 12-month vaccination (Month 13)
Groups 1a and 2a: Percentage of Participants Who Achieved Vaccine Response for Varicella Antibodies at Day 30 Post 12-Month Vaccination
Vaccine response against anti-varicella antibodies were measured by glycoprotein (gp) ELISA. Percentage of participants with anti-varicella antibody concentration \>=5 antibody (Ab) gpELISA units/mL are reported. Percentages are rounded off to the tenth decimal place.
Time frame: Day 30 post 12-month vaccination (Month 13)
Groups 1a and 2a: GMCs of Anti-Pneumococcal Antibodies at Day 30 Post 12-Month Vaccination
GMCs of anti-pneumococcal antibodies was assessed by PnPS IgG ECL assay which is used to quantitate the amount of anti-streptococcus pneumoniae PS (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) antibodies in human serum.
Time frame: Day 30 post 12-month vaccination (Month 13)
Groups 1b and 2b: Percentage of Participants Who Achieved Anti-PRP Antibody Concentrations >=1.0 mcg/mL at Day 30 Post 15-Month Vaccination
Anti-PRP concentrations were measured using a farr-type RIA. The percentage of participants with an PRP antibody titers \>=1.0 mcg/mL were assessed. Percentages are rounded off to the tenth decimal place.
Time frame: Day 30 post 15-month vaccination (Month 16)
Groups 1b and 2b: Percentage of Participants Who Achieved Anti-Poliovirus Antibody Titers >=1:8 at Day 30 Post 15-Month Vaccination
Anti-poliovirus types 1, 2, and 3 were measured by neutralization assay. The percentage of participants with anti-polio antibody titers \>=1:8 are assessed.
Time frame: Day 30 post 15-month vaccination (Month 16)
Groups 1b and 2b: Percentage of Participants Who Achieved Vaccine Response for Anti-Pertussis Antibodies at Day 30 Post 15-Month Vaccination
Vaccine response was defined as: if the pre-booster (4th) vaccination concentration was \<lower limit of quantification (LLOQ), then the post-booster (4th) vaccination concentration should be \>=4 times LLOQ. The LLOQ was equal to 2.00 EU/mL. Percentages are rounded off to the tenth decimal place.
Time frame: Day 30 post 15-month vaccination (Month 16)
Groups 1a and 2a: Geometric Mean Titers (GMTs) of Antibodies Against Meningococcal Serogroups A, C, Y, and W Measured by hSBA at Day 30 Post 6-Month Vaccination and Day 0 Before 12-Month Vaccination
GMTs of antibody against meningococcal serogroups A, C, Y, and W were measured by hSBA. PPAS2 included participants of FAS2 (subset of all randomized participants who received \>=1 dose of the study vaccine in infancy \[at Visit 1 to 3, \< 12 months of age\] and had a valid pre-vaccination serology result at Visit 5 before the 12-month vaccinations for Subgroups 1a and 2a or at Visit 6 before the 15-month vaccinations for Subgroups 1b and 2b) with no relevant protocol deviations during infancy and for whom a pre-dose serology sample at Visit 5 for Subgroups 1a and 2a before the 12-month vaccinations or Visit 6 for Subgroups 1b and 2b before the 15-month vaccinations was not withdrawn.
Time frame: Day 30 post 6-month vaccination (Month 7) and Day 0 before 12-month vaccination (Month 12)
Groups 1a and 2a: Percentage of Participants Who Achieved Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W at Day 30 Post 6-Month Vaccination and Day 0 Before 12-Month Vaccination
Antibody titers of Meningococcal Serogroups A, C, Y, and W were measured by hSBA assay. PPAS2 included participants of FAS2 with no relevant protocol deviations during infancy and for whom a pre-dose serology sample at Visit 5 for Subgroups 1a and 2a before the 12-month vaccinations or Visit 6 for Subgroups 1b and 2b before the 15-month vaccinations was not withdrawn. Percentages are rounded off to the tenth decimal place.
Time frame: Day 30 post 6-month vaccination (Month 7) and Day 0 before 12-month vaccination (Month 12)
The study was conducted at 69 investigational sites in Puerto Rico and the United States. Healthy infants aged \>=42 to \<=89 days were randomized in 2:1 ratio to either Group 1: Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid conjugate vaccine (MenACYW conjugate vaccine) and routine pediatric vaccines or Group 2: Meningococcal (groups A, C, Y, and W-135) oligosaccharide diphtheria cross reacting material (CRM) 197 conjugate vaccine (MENVEO®) and routine pediatric vaccines.
| Milestone | Group 1: MenACYW Conjugate Vaccine | Group 2: MENVEO |
|---|---|---|
| Started | 1746 | 881 |
| Safety analysis set (safas) | 1727 | 867 |
| Vaccinated at 2 months | 1727 | 869 |
| Vaccinated at 4 months | 1619 | 828 |
| Vaccinated at 6 months | 1543 | 793 |
| Vaccinated at 12 months | 1411 | 708 |
| Vaccinated at 15 months | 445 | 644 |
| Completed | 1330 | 623 |
| Not completed | 416 | 258 |
| Withdrew: Adverse event | 2 | 1 |
| Withdrew: Protocol violation | 65 | 48 |
| Withdrew: Lost to follow-up | 86 | 60 |
| Withdrew: Withdrawal by parent/guardian | 263 | 149 |
Functional meningococcal antibody activity against serogroups A, C, Y, and W were measured in a serum bactericidal assay utilizing the hSBA. Vaccine seroresponse was defined as a post 4th dose (Day 30 after 12-month) hSBA titer \>=1:16 for participants with pre 1st dose (Day 0 before 2-month) hSBA titer less than (\<) 1:8, or at least a 4-fold increase in hSBA titer from pre-vaccination to post-vaccination for participants with pre-vaccination hSBA titer \>=1:8. Percentages are rounded off to the tenth decimal place.
| percentage of participants | Group 1a:MenACYW Conjugate Vaccine (Post 12-month Vaccination) | Group 2a: MENVEO (Post 12-month Vaccination) |
|---|---|---|
| Serogroup A | 79.4 (75.6 to 82.9) | 77.6 (71.5 to 82.9) |
| Serogroup C | 97.0 (95.1 to 98.3) | 88.2 (83.4 to 92.0) |
| Serogroup Y | 96.4 (94.4 to 97.8) | 92.3 (88.1 to 95.4) |
| Serogroup W | 97.6 (95.9 to 98.7) | 96.4 (93.3 to 98.3) |
Functional meningococcal antibody activity against serogroups A, C, Y, and W were measured in a serum bactericidal assay utilizing the hSBA. Percentages are rounded off to the tenth decimal place.
| percentage of participants | Group 1: MenACYW Conjugate Vaccine | Group 2: MENVEO |
|---|---|---|
| Serogroup A | 77.9 (75.0 to 80.7) | 67.7 (63.0 to 72.2) |
| Serogroup C | 99.0 (98.1 to 99.6) | 91.2 (88.1 to 93.7) |
| Serogroup Y | 98.3 (97.1 to 99.0) | 91.7 (88.7 to 94.2) |
| Serogroup W | 98.6 (97.6 to 99.3) | 92.9 (90.1 to 95.1) |
Anti-Hepatitis B surface antibodies (HBsAg) were measured by the commercially available VITROS ECi/ECiQ immunodiagnostic system using chemiluminescence detection technology. The percentage of participants with an anti-HBsAg antibody titer \>=10 mIU/mL was assessed. Percentages are rounded off to the tenth decimal place.
| percentage of participants | Group 1: MenACYW Conjugate Vaccine | Group 2: MENVEO |
|---|---|---|
| Groups 1 and 2: Percentage of Participants Who Achieved Anti-Hepatitis B Antibody Concentrations >=10 Milli-International Units Per Milliliter (mIU/mL) at Day 30 Post 6-Month Vaccination | 98.6 ± 97.4 | 98.0 ± 95.9 |
Anti-PRP concentrations were measured using a farr-type radioimmunoassay (RIA). The percentage of participants with an PRP antibody titer \>=0.15 mcg/mL and \>=1.0 mcg/mL were assessed. Percentages are rounded off to the tenth decimal place.
| percentage of participants | Group 1: MenACYW Conjugate Vaccine | Group 2: MENVEO |
|---|---|---|
| >=0.15 mcg/mL | 99.0 ± 98.1 | 96.4 ± 94.2 |
| >=1.0 mcg/mL | 91.3 ± 89.2 | 85.7 ± 82.0 |
Anti-poliovirus types 1, 2, and 3 were measured by neutralization assay. The percentage of participants with anti-polio antibody titers \>=1:8 were assessed.
| percentage of participants | Group 1: MenACYW Conjugate Vaccine | Group 2: MENVEO |
|---|---|---|
| Anti-polio 1 | 100 (99.6 to 100) | 100 (99.1 to 100) |
| Anti-polio 2 | 100 (99.6 to 100) | 100 (99.1 to 100) |
| Anti-polio 3 | 100 (99.6 to 100) | 100 (99.1 to 100) |
Anti-rotavirus IgA antibodies in human serum were measured by enzyme-linked immunosorbent assay (ELISA). The percentage of participants who achieved anti-rotavirus IgA Ab concentrations \>=3-fold rise were assessed. Percentages are rounded off to the tenth decimal place.
| percentage of participants | Group 1: MenACYW Conjugate Vaccine | Group 2: MENVEO |
|---|---|---|
| Groups 1 and 2: Percentage of Participants Who Achieved Anti-Rotavirus Immunoglobulin A (IgA) Antibody Concentrations >=3-Fold Rise at Day 30 Post 6-Month Vaccination | 91.0 ± 88.5 | 92.8 ± 89.4 |
GMCs of anti-rotavirus serum IgA antibodies were assessed using ELISA.
| Units/mL | Group 1: MenACYW Conjugate Vaccine | Group 2: MENVEO |
|---|---|---|
| Groups 1 and 2: Geometric Mean Concentrations (GMCs) of Anti-Rotavirus IgA Antibodies at Day 30 Post 6-Month Vaccination | 272 ± 244 | 308 ± 264 |
GMCs of anti-pertussis antibodies (pertussis toxoid \[PT\], filamentous hemagglutinin adhesin \[FHA\], pertactin \[PRN\] and fimbriae types 2 and 3 \[FIM\]) were measured by electrochemiluminescent (ECL) assay.
| ELISA units/mL | Group 1: MenACYW Conjugate Vaccine | Group 2: MENVEO |
|---|---|---|
| Anti-PT | 75.8 ± 72.2 | 78.6 ± 72.8 |
| Anti-FHA | 95.7 ± 90.9 | 98.6 ± 91.7 |
| Anti-PRN | 39.4 ± 36.8 | 42.1 ± 37.9 |
| Anti-FIM | 309 ± 291 | 311 ± 284 |
GMCs of anti-pneumococcal antibodies was assessed by pneumococcal capsular polysaccharide (PnPS) IgG ECL assay which is used to quantitate the amount of anti-streptococcus pneumoniae PS (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) antibodies in human serum.
| mcg/mL | Group 1: MenACYW Conjugate Vaccine | Group 2: MENVEO |
|---|---|---|
| Serotype 1 | 2.26 (2.13 to 2.40) | 1.93 (1.77 to 2.12) |
| Serotype 3 | 0.607 (0.577 to 0.638) | 0.544 (0.505 to 0.585) |
| Serotype 4 | 1.46 (1.40 to 1.53) | 1.33 (1.24 to 1.42) |
| Serotype 5 | 1.54 (1.46 to 1.63) | 1.26 (1.15 to 1.37) |
| Serotype 6A | 4.01 (3.82 to 4.22) | 3.34 (3.09 to 3.62) |
| Serotype 6B | 2.47 (2.29 to 2.67) | 1.97 (1.75 to 2.21) |
| Serotype 7F | 3.48 (3.32 to 3.64) | 3.40 (3.18 to 3.63) |
| Serotype 9V | 1.88 (1.78 to 1.99) | 1.61 (1.48 to 1.74) |
| Serotype 14 | 6.95 (6.53 to 7.41) | 7.17 (6.58 to 7.81) |
| Serotype 18C | 1.95 (1.86 to 2.04) | 1.82 (1.69 to 1.96) |
| Serotype 19A | 2.21 (2.10 to 2.32) | 2.00 (1.86 to 2.14) |
| Serotype 19F | 3.36 (3.21 to 3.52) | 2.98 (2.77 to 3.21) |
| Serotype 23F | 1.59 (1.49 to 1.69) | 1.30 (1.18 to 1.44) |
Vaccine response against anti-measles and anti-rubella antibodies were measured by bulk IgG enzyme immunoassay and anti-mumps antibodies were assessed by ELISA. Percentage of participants with anti-measles, anti-mumps, anti-rubella antibody concentration that met the respective mentioned criterion are reported: measles: \>=255 mIU/mL; mumps: \>=10 antibody units per milliliter and rubella: \>=10 IU/mL. Percentages are rounded off to the tenth decimal place.
| percentage of participants | Group 1a:MenACYW Conjugate Vaccine (Post 12-month Vaccination) | Group 2a: MENVEO (Post 12-month Vaccination) |
|---|---|---|
| Anti-measles | 97.6 (96.1 to 98.6) | 97.3 (94.8 to 98.8) |
| Anti-mumps | 95.5 (93.6 to 96.9) | 97.7 (95.3 to 99.1) |
| Anti-rubella | 97.9 (96.5 to 98.8) | 98.0 (95.7 to 99.3) |
Vaccine response against anti-varicella antibodies were measured by glycoprotein (gp) ELISA. Percentage of participants with anti-varicella antibody concentration \>=5 antibody (Ab) gpELISA units/mL are reported. Percentages are rounded off to the tenth decimal place.
| percentage of participants | Group 1a:MenACYW Conjugate Vaccine (Post 12-month Vaccination) | Group 2a: MENVEO (Post 12-month Vaccination) |
|---|---|---|
| Groups 1a and 2a: Percentage of Participants Who Achieved Vaccine Response for Varicella Antibodies at Day 30 Post 12-Month Vaccination | 96.4 (94.7 to 97.7) | 94.7 (91.5 to 96.9) |
GMCs of anti-pneumococcal antibodies was assessed by PnPS IgG ECL assay which is used to quantitate the amount of anti-streptococcus pneumoniae PS (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) antibodies in human serum.
| mcg/mL | Group 1a:MenACYW Conjugate Vaccine (Post 12-month Vaccination) | Group 2a: MENVEO (Post 12-month Vaccination) |
|---|---|---|
| Serotype 1 | 3.81 (3.56 to 4.08) | 3.44 (3.12 to 3.81) |
| Serotype 3 | 0.771 (0.728 to 0.817) | 0.751 (0.690 to 0.818) |
| Serotype 4 | 2.08 (1.95 to 2.22) | 2.00 (1.83 to 2.18) |
| Serotype 5 | 2.70 (2.53 to 2.88) | 2.46 (2.25 to 2.69) |
| Serotype 6A | 9.65 (9.09 to 10.2) | 9.51 (8.72 to 10.4) |
| Serotype 6B | 7.41 (6.92 to 7.93) | 6.37 (5.77 to 7.03) |
| Serotype 7F | 5.40 (5.08 to 5.73) | 6.04 (5.56 to 6.55) |
| Serotype 9V | 3.53 (3.31 to 3.77) | 3.62 (3.30 to 3.96) |
| Serotype 14 | 7.80 (7.26 to 8.38) | 9.20 (8.37 to 10.1) |
| Serotype 18C | 2.60 (2.44 to 2.78) | 2.92 (2.68 to 3.19) |
| Serotype 19A | 6.19 (5.82 to 6.59) | 5.86 (5.32 to 6.45) |
| Serotype 19F | 6.49 (6.11 to 6.90) | 6.01 (5.45 to 6.62) |
| Serotype 23F | 3.88 (3.60 to 4.17) | 3.41 (3.09 to 3.78) |
Anti-PRP concentrations were measured using a farr-type RIA. The percentage of participants with an PRP antibody titers \>=1.0 mcg/mL were assessed. Percentages are rounded off to the tenth decimal place.
| percentage of participants | Group 1b:MenACYW Conjugate Vaccine(Post 15-month Vaccination) | Group 2b: MENVEO (Post 15- Month Vaccination) |
|---|---|---|
| Groups 1b and 2b: Percentage of Participants Who Achieved Anti-PRP Antibody Concentrations >=1.0 mcg/mL at Day 30 Post 15-Month Vaccination | 98.3 (96.1 to 99.5) | 98.4 (94.3 to 99.8) |
Anti-poliovirus types 1, 2, and 3 were measured by neutralization assay. The percentage of participants with anti-polio antibody titers \>=1:8 are assessed.
| percentage of participants | Group 1b:MenACYW Conjugate Vaccine(Post 15-month Vaccination) | Group 2b: MENVEO (Post 15- Month Vaccination) |
|---|---|---|
| Anti-polio 1 | 100 (98.7 to 100) | 100 (97.0 to 100) |
| Anti-polio 2 | 100 (98.7 to 100) | 100 (97.0 to 100) |
| Anti-polio 3 | 100 (98.7 to 100) | 100 (97.0 to 100) |
Vaccine response was defined as: if the pre-booster (4th) vaccination concentration was \<lower limit of quantification (LLOQ), then the post-booster (4th) vaccination concentration should be \>=4 times LLOQ. The LLOQ was equal to 2.00 EU/mL. Percentages are rounded off to the tenth decimal place.
| percentage of participants | Group 1b:MenACYW Conjugate Vaccine(Post 15-month Vaccination) | Group 2b: MENVEO (Post 15- Month Vaccination) |
|---|---|---|
| Anti-PT | 98.5 (96.3 to 99.6) | 98.3 (94.2 to 99.8) |
| Anti-FHA | 96.7 (93.8 to 98.5) | 96.7 (91.8 to 99.1) |
| Anti-PRN | 96.3 (93.4 to 98.2) | 97.5 (92.9 to 99.5) |
| Anti-FIM | 98.2 (95.8 to 99.4) | 97.5 (92.9 to 99.5) |
GMTs of antibody against meningococcal serogroups A, C, Y, and W were measured by hSBA. PPAS2 included participants of FAS2 (subset of all randomized participants who received \>=1 dose of the study vaccine in infancy \[at Visit 1 to 3, \< 12 months of age\] and had a valid pre-vaccination serology result at Visit 5 before the 12-month vaccinations for Subgroups 1a and 2a or at Visit 6 before the 15-month vaccinations for Subgroups 1b and 2b) with no relevant protocol deviations during infancy and for whom a pre-dose serology sample at Visit 5 for Subgroups 1a and 2a before the 12-month vaccinations or Visit 6 for Subgroups 1b and 2b before the 15-month vaccinations was not withdrawn.
| titer | Group 1a:MenACYW Conjugate Vaccine (Post 12-month Vaccination) | Group 2a: MENVEO (Post 12- Month Vaccination) |
|---|---|---|
| Serogroup A: Day 30 post 3rd dose | 24.9 (21.6 to 28.6) | 16.3 (13.5 to 19.6) |
| Serogroup A: Day 0 before 4th dose | 9.33 (8.45 to 10.3) | 6.43 (5.64 to 7.33) |
| Serogroup C: Day 30 post 3rd dose | 365 (325 to 411) | 51.4 (42.9 to 61.5) |
| Serogroup C: Day 0 before 4th dose | 57.8 (51.5 to 64.8) | 4.82 (4.22 to 5.50) |
| Serogroup Y: Day 30 post 3rd dose | 83.0 (75.0 to 91.8) | 42.9 (36.7 to 50.0) |
| Serogroup Y: Day 0 before 4th dose | 42.9 (39.3 to 46.7) | 10.4 (9.15 to 11.9) |
| Serogroup W: Day 30 post 3rd dose | 92.8 (84.8 to 102) | 51.4 (43.9 to 60.0) |
| Serogroup W: Day 0 before 4th dose | 57.8 (52.7 to 63.3) | 9.27 (8.15 to 10.5) |
Antibody titers of Meningococcal Serogroups A, C, Y, and W were measured by hSBA assay. PPAS2 included participants of FAS2 with no relevant protocol deviations during infancy and for whom a pre-dose serology sample at Visit 5 for Subgroups 1a and 2a before the 12-month vaccinations or Visit 6 for Subgroups 1b and 2b before the 15-month vaccinations was not withdrawn. Percentages are rounded off to the tenth decimal place.
| percentage of participants | Group 1a:MenACYW Conjugate Vaccine (Post 12-month Vaccination) | Group 2a: MENVEO (Post 12- Month Vaccination) |
|---|---|---|
| Serogroup A: D30 post 3rd dose:>=1:4 | 87.0 (83.9 to 89.7) | 84.9 (79.9 to 89.0) |
| Serogroup A: D30 post 3rd dose:>=1:8 | 77.3 (73.6 to 80.8) | 70.2 (64.2 to 75.7) |
| Serogroup A:D0 before 4th dose:>=1:4 | 82.5 (79.2 to 85.4) | 66.4 (60.9 to 71.5) |
| Serogroup A:D0 before 4th dose:>=1:8 | 59.0 (55.0 to 62.9) | 47.0 (41.5 to 52.7) |
| Serogroup C: D30 post 3rd dose:>=1:4 (n=) | 99.3 (98.1 to 99.8) | 93.7 (90.0 to 96.3) |
| Serogroup C: D30 post 3rd dose:>=1:8 | 99.1 (97.9 to 99.7) | 91.0 (87.0 to 94.2) |
| Serogroup C:D0 before 4th dose:>=1:4 | 95.4 (93.5 to 96.9) | 49.1 (43.5 to 54.7) |
| Serogroup C:D0 before 4th dose:>=1:8 | 92.9 (90.7 to 94.8) | 34.0 (28.8 to 39.4) |
| Serogroup Y: D30 post 3rd dose:>=1:4 | 99.1 (97.9 to 99.7) | 96.3 (93.3 to 98.2) |
| Serogroup Y: D30 post 3rd dose:>=1:8 | 98.6 (97.2 to 99.4) | 92.2 (88.4 to 95.1) |
| Serogroup Y:D0 before 4th dose:>=1:4 | 99.2 (98.2 to 99.7) | 83.5 (79.0 to 87.3) |
| Serogroup Y:D0 before 4th dose:>=1:8 | 96.8 (95.2 to 98.1) | 69.1 (63.8 to 74.1) |
| Serogroup W: D30 post 3rd dose:>=1:4 | 99.8 (99.0 to 100) | 97.5 (94.9 to 99.0) |
| Serogroup W: D30 post 3rd dose:>=1:8 | 98.8 (97.5 to 99.5) | 94.2 (90.8 to 96.7) |
| Serogroup W:D0 before 4th dose:>=1:4 | 98.9 (97.8 to 99.6) | 82.7 (78.1 to 86.6) |
| Serogroup W:D0 before 4th dose:>=1:8 | 97.2 (95.6 to 98.3) | 62.0 (56.5 to 67.3) |
Collected over From first administration of study treatment (Day 0) up to 6-months post last administration of study treatment, approximately 24 months for Group 1 and 18 months for Group 2.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group 1: MenACYW Conjugate Vaccine | 1/1,727 (0.1%) | 99/1,727 (5.7%) | 1,471/1,727 (85.2%) |
| Group 2: MENVEO | 0/867 (0%) | 38/867 (4.4%) | 746/867 (86%) |
| Event | Group 1: MenACYW Conjugate Vaccine | Group 2: MENVEO |
|---|---|---|
| BronchiolitisInfections and infestations | 15/1727 | 4/867 |
| Respiratory Syncytial Virus InfectionInfections and infestations | 7/1727 | 6/867 |
| Respiratory Syncytial Virus BronchiolitisInfections and infestations | 9/1727 | 4/867 |
| Febrile ConvulsionNervous system disorders | 8/1727 | 3/867 |
| DehydrationMetabolism and nutrition disorders | 3/1727 | 4/867 |
| PneumoniaInfections and infestations | 6/1727 | 2/867 |
| GastroenteritisInfections and infestations | 2/1727 | 3/867 |
| Urinary Tract InfectionInfections and infestations | 2/1727 | 3/867 |
| Respiratory DistressRespiratory, thoracic and mediastinal disorders | 4/1727 | 3/867 |
| InfluenzaInfections and infestations | 4/1727 | 1/867 |
| Event | Group 1: MenACYW Conjugate Vaccine | Group 2: MENVEO |
|---|---|---|
| Injection Site PainGeneral disorders | 1201/1727 | 637/867 |
| IrritabilityPsychiatric disorders | 1154/1727 | 598/867 |
| CryingGeneral disorders | 1023/1727 | 541/867 |
| SomnolenceNervous system disorders | 975/1727 | 507/867 |
| Injection Site ErythemaGeneral disorders | 806/1727 | 409/867 |
| Decreased AppetiteMetabolism and nutrition disorders | 704/1727 | 388/867 |
| Injection Site SwellingGeneral disorders | 632/1727 | 323/867 |
| PyrexiaGeneral disorders | 580/1727 | 312/867 |
| VomitingGastrointestinal disorders | 417/1727 | 196/867 |
| Upper Respiratory Tract InfectionInfections and infestations | 214/1727 | 130/867 |
Baseline characteristics were assessed for all randomized participants.
| Age, Continuous(days) | Group 1: MenACYW Conjugate Vaccine | Group 2: MENVEO | Total |
|---|---|---|---|
| Mean | 65.3 ± 8.02 | 65.3 ± 7.81 | 65.3 ± 7.95 |
| Sex: Female, Male(Participants) | Group 1: MenACYW Conjugate Vaccine | Group 2: MENVEO | Total |
|---|---|---|---|
| Female | 828 | 415 | 1243 |
| Male | 918 | 466 | 1384 |
| Race (NIH/OMB)(Participants) | Group 1: MenACYW Conjugate Vaccine | Group 2: MENVEO | Total |
|---|---|---|---|
| American Indian or Alaska Native | 11 | 3 | 14 |
| Asian | 15 | 10 | 25 |
| Native Hawaiian or Other Pacific Islander | 7 | 6 | 13 |
| Black or African American | 204 | 99 | 303 |
| White | 1428 | 722 | 2150 |
| More than one race | 44 | 30 | 74 |
| Unknown or Not Reported | 37 | 11 | 48 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Ran from Apr 2018 to primary completion in Sep 2023, 64 months.
Results were first posted in Oct 2024, 1 year after primary completion.
Of 46 industry-sponsored phase 3 interventional studies under Meningococcal Infections, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 40. This study's 64 months is above that.
Counting every sponsor, half of 46 studies reached it within 15 months; a quarter within 8 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sanofi Pasteur, a Sanofi Company →